Promestriene
[CAS# 39219-28-8]

Identification

• Classification: API >> Hormone and endocrine-regulating drugs >> Estrogen and progestogen drugs
• Name: Promestriene
• Synonyms: 3-Propoxy-17beta-methoxy-1,3,5(10)-estratriene
• Molecular Formula: C₂₂H₃₂O₂
• Molecular Weight: 328.49
• CAS Registry Number: 39219-28-8
• EC Number: 254-361-6
• SMILES: CCCOC1=CC2=C(C=C1)C3CCC4(C(C3CC2)CCC4OC)C

Safety Data

• Hazard Symbols: GHS07;GHS08 Warning
• Risk Statements: H302-H312-H332-H360
• Safety Statements: P203-P261-P264-P270-P271-P280-P301+P317-P302+P352-P304+P340-P317-P318-P321-P330-P362+P364-P405-P501

Hazard Classification

Hazard	Class	Category Code	Hazard Statement
Acute toxicity	Acute Tox.	4	H312
Reproductive toxicity	Repr.	1A	H360
Acute toxicity	Acute Tox.	4	H302
Acute toxicity	Acute Tox.	4	H332

Discovery and Applications

Promestriene is a synthetic estrogen with notable applications in the treatment of menopausal symptoms and certain gynecological conditions. Its chemical structure, derived from estrogens, contributes to its efficacy in hormone therapy. Promestriene has been used therapeutically to manage various health issues related to estrogen deficiency.

The discovery of promestriene is linked to the broader research into estrogenic compounds aimed at developing treatments for menopause and related conditions. Synthesized in the mid-20th century, promestriene was designed to offer therapeutic benefits while minimizing side effects associated with other estrogens. Its structure includes a phenolic group and a ketone group, which play a crucial role in its estrogenic activity.

In clinical practice, promestriene is primarily used in the management of symptoms associated with menopause. It helps alleviate common menopausal symptoms such as vaginal dryness, atrophy, and discomfort. By mimicking the effects of natural estrogen, promestriene aids in maintaining the health and function of the vaginal mucosa, thereby improving the quality of life for postmenopausal women. Its use in estrogen replacement therapy is valued for its ability to provide localized treatment with a lower risk of systemic side effects compared to other estrogens.

Promestriene is also employed in the treatment of certain gynecological conditions, including vaginal atrophy and postmenopausal urogenital syndrome. The compound is available in various formulations, such as vaginal creams or suppositories, which allow for targeted application and effective management of symptoms. This localized application helps in reducing the risk of systemic absorption and associated side effects.

The development and use of promestriene have been accompanied by ongoing research into its safety and efficacy. Studies have focused on understanding the compound's pharmacokinetics, optimal dosing, and long-term effects. This research is crucial for ensuring the safe and effective use of promestriene in hormone therapy and other medical applications.

Handling promestriene requires standard precautions due to its pharmacological activity. Proper use and storage are essential to maintain the compound's efficacy and ensure patient safety. Healthcare professionals should provide guidance on the correct application and dosage to achieve the desired therapeutic outcomes.

In summary, promestriene is an important synthetic estrogen used in the treatment of menopausal symptoms and certain gynecological conditions. Its discovery and development have provided valuable options for hormone therapy, improving the quality of life for women experiencing estrogen deficiency. Ongoing research continues to support its use and explore further applications.

References

2022. Effects of oxytocin versus promestriene on genitourinary syndrome: a pilot, prospective, randomized, double-blind study. Clinics (Sao Paulo, Brazil), 77.
DOI: 10.1016/j.clinsp.2022.100116

2020. Efficacy of Fractional CO2 Laser, Promestriene, and Vaginal Lubricant in the Treatment of Urinary Symptoms in Postmenopausal Women: A Randomized Clinical Trial. Lasers in Surgery and Medicine, 52(8).
DOI: 10.1002/lsm.23220

1983. The percutaneous absorption and excretion of promestriene (3-propoxy-17 beta-methoxy-1,3,5(10)-estratriene) in rats and humans. Steroids, 41(1).
DOI: 10.1016/0039-128x(83)90012-0